Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV safety study of CEDARCURE SLIT-tablet and MITICURE SLIT-tablet combination therapy
jRCT1080223956Phase 4Completed
- Sponsor
- Torii Pharmaceutical
- Start
- Jun 2018
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of japanese cedar pollen and House dust mite allergen extract in Japanese cedar pollinosis and allergic rhinitis (AR), sponsored by Torii Pharmaceutical. Started Jun 2018; status: completed.
02
Drugs
japanese cedar pollenHouse dust mite allergen extract
03
Conditions
Japanese cedar pollinosisallergic rhinitis (AR)
Beyond the preview
Go deeper on jRCT1080223956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223956.